DR   cancercelllines; CVCL_RN09
DR   Wikidata; Q54946849
RX   PubMed=27031228;
RX   PubMed=27328060;
RX   PubMed=27564251;
RX   PubMed=28101903;
CC   Problematic cell line: Contaminated. Parent cell line (LN-319) has been shown to be a LN-992 derivative.
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Brain, right temporal lobe; UBERON=UBERON_0002809.
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3958 ! LN-319
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 30-01-24; Version: 8
RX   PubMed=27031228; DOI=10.1371/journal.pone.0152912;
RA   Kato Y., Ogasawara S., Oki H., Goichberg P., Honma R., Fujii Y.,
RA   Kaneko M.K.;
RT   "LpMab-12 established by CasMab technology specifically detects
RT   sialylated O-glycan on Thr52 of platelet aggregation-stimulating
RT   domain of human podoplanin.";
RL   PLoS ONE 11:E0152912-E0152912(2016).
RX   PubMed=27328060; DOI=10.1089/mab.2016.0006;
RA   Ogasawara S., Kaneko M.K., Honma R., Oki H., Fujii Y., Takagi M.,
RA   Suzuki H., Kato Y.;
RT   "Establishment of mouse monoclonal antibody LpMab-13 against human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:155-162(2016).
RX   PubMed=27564251; DOI=10.1089/mab.2016.0031;
RA   Ogasawara S., Kaneko M.K., Kato Y.;
RT   "LpMab-19 recognizes sialylated O-Glycan on Thr76 of human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:245-253(2016).
RX   PubMed=28101903; DOI=10.1002/cam4.954;
RA   Kaneko M.K., Nakamura T., Honma R., Ogasawara S., Fujii Y., Abe S.,
RA   Takagi M., Harada H., Suzuki H., Nishioka Y., Kato Y.;
RT   "Development and characterization of anti-glycopeptide monoclonal
RT   antibodies against human podoplanin, using glycan-deficient cell lines
RT   generated by CRISPR/Cas9 and TALEN.";
RL   Cancer Med. 6:382-396(2017).